JP2013528204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528204A5 JP2013528204A5 JP2013513758A JP2013513758A JP2013528204A5 JP 2013528204 A5 JP2013528204 A5 JP 2013528204A5 JP 2013513758 A JP2013513758 A JP 2013513758A JP 2013513758 A JP2013513758 A JP 2013513758A JP 2013528204 A5 JP2013528204 A5 JP 2013528204A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methylmorpholin
- methylsulfonimidoyl
- amine
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 125000004429 atoms Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- -1 3-methylmorpholin-4-yl Chemical group 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- YXSYJGJKBNBZLQ-BRRNQIAESA-N 1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(N2C3=CC=CC=C3N=C2N)=N1 YXSYJGJKBNBZLQ-BRRNQIAESA-N 0.000 claims 1
- YXSYJGJKBNBZLQ-OSXTUODASA-N 1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@@](C)(=N)=O)=NC(N2C3=CC=CC=C3N=C2N)=N1 YXSYJGJKBNBZLQ-OSXTUODASA-N 0.000 claims 1
- WUJFVGIVMGNTPV-FZAOIFNZSA-N 4-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CC1 WUJFVGIVMGNTPV-FZAOIFNZSA-N 0.000 claims 1
- WUJFVGIVMGNTPV-RZQXLCLMSA-N 4-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CC1 WUJFVGIVMGNTPV-RZQXLCLMSA-N 0.000 claims 1
- HQFFRTPOWLGAIX-FZAOIFNZSA-N 4-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C HQFFRTPOWLGAIX-FZAOIFNZSA-N 0.000 claims 1
- HQFFRTPOWLGAIX-RZQXLCLMSA-N 4-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=C(F)C=CC=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C HQFFRTPOWLGAIX-RZQXLCLMSA-N 0.000 claims 1
- IVKZEHQGPBBLPD-FZAOIFNZSA-N 5-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC(F)=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CC1 IVKZEHQGPBBLPD-FZAOIFNZSA-N 0.000 claims 1
- IVKZEHQGPBBLPD-RZQXLCLMSA-N 5-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC(F)=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CC1 IVKZEHQGPBBLPD-RZQXLCLMSA-N 0.000 claims 1
- FGTJUHKILGGMAK-FZAOIFNZSA-N 5-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC(F)=CC=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C FGTJUHKILGGMAK-FZAOIFNZSA-N 0.000 claims 1
- FGTJUHKILGGMAK-RZQXLCLMSA-N 5-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC(F)=CC=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C FGTJUHKILGGMAK-RZQXLCLMSA-N 0.000 claims 1
- AORKOLDGMLWWPG-RZQXLCLMSA-N 6-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=C(F)C=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CC1 AORKOLDGMLWWPG-RZQXLCLMSA-N 0.000 claims 1
- PSIPSQLSHTYKJT-FZAOIFNZSA-N 6-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=C(F)C=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C PSIPSQLSHTYKJT-FZAOIFNZSA-N 0.000 claims 1
- PSIPSQLSHTYKJT-RZQXLCLMSA-N 6-fluoro-N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=C(F)C=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C PSIPSQLSHTYKJT-RZQXLCLMSA-N 0.000 claims 1
- JESNSKPPMWEWAT-JKGBWWFKSA-N N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CC1 JESNSKPPMWEWAT-JKGBWWFKSA-N 0.000 claims 1
- JESNSKPPMWEWAT-YSVRNHBLSA-N N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CC1 JESNSKPPMWEWAT-YSVRNHBLSA-N 0.000 claims 1
- LRIFUSYFLXZCKX-JKGBWWFKSA-N N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=C(C=1)C(C)(C)[S@](C)(=N)=O)=NC=1N1CCOC[C@H]1C LRIFUSYFLXZCKX-JKGBWWFKSA-N 0.000 claims 1
- LRIFUSYFLXZCKX-YSVRNHBLSA-N N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[2-(methylsulfonimidoyl)propan-2-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=C(C=1)C(C)(C)[S@@](C)(=N)=O)=NC=1N1CCOC[C@H]1C LRIFUSYFLXZCKX-YSVRNHBLSA-N 0.000 claims 1
- YIASZZUGUQHGBB-JTJFVBHCSA-N N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[4-(methylsulfonimidoyl)oxan-4-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@](C)(=N)=O)CCOCC1 YIASZZUGUQHGBB-JTJFVBHCSA-N 0.000 claims 1
- YIASZZUGUQHGBB-RZCFMFBHSA-N N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-[4-(methylsulfonimidoyl)oxan-4-yl]pyrimidin-2-yl]benzimidazol-2-amine Chemical compound CNC1=NC2=CC=CC=C2N1C(N=1)=NC(N2[C@@H](COCC2)C)=CC=1C1([S@@](C)(=N)=O)CCOCC1 YIASZZUGUQHGBB-RZCFMFBHSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- OOEYPUFPMHMEAP-IZPCHGGPSA-N imino-[1-[2-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl]cyclopropyl]-methyl-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 OOEYPUFPMHMEAP-IZPCHGGPSA-N 0.000 claims 1
- OOEYPUFPMHMEAP-ONSXPEOJSA-N imino-[1-[2-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl]cyclopropyl]-methyl-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@@](C)(=N)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 OOEYPUFPMHMEAP-ONSXPEOJSA-N 0.000 claims 1
- IFKRIACODANJFM-FTDQSSOUSA-N imino-[4-[2-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl]oxan-4-yl]-methyl-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CCOCC2)[S@@](C)(=N)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 IFKRIACODANJFM-FTDQSSOUSA-N 0.000 claims 1
- OHUHVTCQTUDPIJ-MUWSIPGASA-N imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-MUWSIPGASA-N 0.000 claims 1
- DTTJKLNXNZAVSM-RNHBAAACSA-N imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)S(C)(=N)=O)=NC(C=2C=3C=CNC=3C=NC=2)=N1 DTTJKLNXNZAVSM-RNHBAAACSA-N 0.000 claims 1
- FEFZJKWFEQKDHO-KHXSAUHESA-N imino-methyl-[[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]methyl]-oxo-$l^{6}-sulfane Chemical compound C[C@@H]1COCCN1C1=CC(C[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 FEFZJKWFEQKDHO-KHXSAUHESA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
Claims (13)
- 式(I):
R2は、
nは、0または1であり;
R2A、R2C、R2EおよびR2Fは、各々独立して、水素またはメチルであり;
R2BおよびR2Dは、各々独立して、水素またはメチルであり;
R2Gは、−NHR7および−NHCOR8より選択され;
R2Hは、フルオロであり;
R3は、メチルであり;
R4およびR5は、各々独立して、水素またはメチルであり、またはR4およびR5は、それらが結合している原子と一緒になって、環Aを形成し;
環Aは、C3−6シクロアルキル、またはOおよびNより選択される1個のヘテロ原子を含有する飽和4〜6員複素環式環であり;
R6は、水素であり;
R7は、水素またはメチルであり;
R8は、メチルである)
を有する化合物、またはその薬学的に許容しうる塩。 - R4およびR5が、それらが結合している原子と一緒になって、環Aを形成し、そして環Aが、C3−6シクロアルキル、またはOおよびNより選択される1個のヘテロ原子を含有する飽和4〜6員複素環式環である、請求項1に記載の化合物。
- 環Aが、シクロプロピル環、テトラヒドロピラニル環またはピペリジニル環である、請求項1または請求項2に記載の化合物。
- R2Aが、水素であり;R2Bが、水素であり;R2Cが、水素であり;R2Dが、水素であり;R2Eが、水素であり;そしてR2Fが、水素である、請求項1〜3のいずれか1項に記載の化合物。
- R1が、3−メチルモルホリン−4−イルである、請求項1〜4のいずれか1項に記載の化合物。
- 式(I)の化合物が、
4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[((R)−S−メチルスルホンイミドイル)メチル]ピリミジン−2−イル}−1H−ピロロ[2,3−b]ピリジン;
4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ピロロ[2,3−b]ピリジン;
4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ピロロ[2,3−b]ピリジン;
N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−インドール;
4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−インドール;
1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
4−フルオロ−N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
4−フルオロ−N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−(S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ピロロ[2,3−c]ピリジン;
N−メチル−1−{4−[1−メチル−1−((S)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
N−メチル−1−{4−[1−メチル−1−((R)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[4−((S)−S−メチルスルホンイミドイル)テトラヒドロ−2H−ピラン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[4−((R)−S−メチルスルホンイミドイル)テトラヒドロ−2H−ピラン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[4−((S)−S−メチルスルホンイミドイル)テトラヒドロ−2H−ピラン−4−イル]ピリミジン−2−イル}−1H−インドール;
4−フルオロ−N−メチル−1−{4−[1−メチル−1−((S)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
4−フルオロ−N−メチル−1−{4−[1−メチル−1−((R)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
6−フルオロ−N−メチル−1−{4−[1−メチル−1−((R)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
5−フルオロ−N−メチル−1−{4−[1−メチル−1−((R)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
5−フルオロ−N−メチル−1−{4−[1−メチル−1−((S)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
6−フルオロ−N−メチル−1−{4−[1−メチル−1−((S)−S−メチルスルホンイミドイル)エチル]−6−[(3R)−3−メチルモルホリン−4−イル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
6−フルオロ−N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
5−フルオロ−N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;
5−フルオロ−N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン;および
6−フルオロ−N−メチル−1−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ベンゾイミダゾール−2−アミン
より選択される、請求項1に記載の化合物またはその薬学的に許容しうる塩。 - 式(I)の化合物が、4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((S)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ピロロ[2,3−b]ピリジンである、請求項1に記載の化合物またはその薬学的に許容しうる塩。
- 式(I)の化合物が、4−{4−[(3R)−3−メチルモルホリン−4−イル]−6−[1−((R)−S−メチルスルホンイミドイル)シクロプロピル]ピリミジン−2−イル}−1H−ピロロ[2,3−b]ピリジンである、請求項1に記載の化合物またはその薬学的に許容しうる塩。
- 癌の処置に用いるための、請求項1〜10のいずれか一項に記載の式(I)の化合物またはその薬学的に許容しうる塩。
- 請求項1〜10のいずれか一項に記載の式(I)の化合物またはその薬学的に許容しうる塩を、薬学的に許容しうるアジュバント、希釈剤または担体と一緒に含む医薬組成物。
- ATRキナーゼの阻害に感受性である腫瘍の予防または処置に用いるための薬剤の製造における、請求項1〜10のいずれか1項に記載の式(I)の化合物またはその薬学的に許容しうる塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35371310P | 2010-06-11 | 2010-06-11 | |
US61/353,713 | 2010-06-11 | ||
PCT/GB2011/051074 WO2011154737A1 (en) | 2010-06-11 | 2011-06-09 | Morpholino pyrimidines and their use in therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013528204A JP2013528204A (ja) | 2013-07-08 |
JP2013528204A5 true JP2013528204A5 (ja) | 2014-07-03 |
JP5721821B2 JP5721821B2 (ja) | 2015-05-20 |
Family
ID=44168987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013513758A Active JP5721821B2 (ja) | 2010-06-11 | 2011-06-09 | モルホリノピリミジンおよび治療におけるそれらの使用 |
Country Status (38)
Country | Link |
---|---|
US (5) | US8252802B2 (ja) |
EP (1) | EP2579877B1 (ja) |
JP (1) | JP5721821B2 (ja) |
KR (1) | KR101820996B1 (ja) |
CN (1) | CN103068391B (ja) |
AR (1) | AR081859A1 (ja) |
AU (1) | AU2011263491B2 (ja) |
BR (1) | BR112012031561B1 (ja) |
CA (1) | CA2800203C (ja) |
CL (1) | CL2012003503A1 (ja) |
CO (1) | CO6640270A2 (ja) |
CR (1) | CR20120628A (ja) |
CU (1) | CU24109B1 (ja) |
DK (1) | DK2579877T3 (ja) |
DO (1) | DOP2012000310A (ja) |
EA (1) | EA022087B1 (ja) |
EC (1) | ECSP12012334A (ja) |
ES (1) | ES2514325T3 (ja) |
GT (1) | GT201200334A (ja) |
HK (1) | HK1182019A1 (ja) |
HR (1) | HRP20140953T1 (ja) |
MX (1) | MX2012014477A (ja) |
MY (1) | MY158193A (ja) |
NI (1) | NI201200184A (ja) |
NZ (1) | NZ604480A (ja) |
PE (1) | PE20130306A1 (ja) |
PL (1) | PL2579877T3 (ja) |
PT (1) | PT2579877E (ja) |
RS (1) | RS53566B1 (ja) |
SA (1) | SA111320519B1 (ja) |
SG (1) | SG185711A1 (ja) |
SI (1) | SI2579877T1 (ja) |
SM (1) | SMT201400146B (ja) |
TW (1) | TWI526208B (ja) |
UA (1) | UA109010C2 (ja) |
UY (1) | UY33440A (ja) |
WO (1) | WO2011154737A1 (ja) |
ZA (1) | ZA201300255B (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
WO2015195740A1 (en) | 2014-06-17 | 2015-12-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
WO2018029117A1 (en) * | 2016-08-10 | 2018-02-15 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | New atr inhibitors for the use in cancer therapy |
JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
AR110995A1 (es) | 2017-02-24 | 2019-05-22 | Bayer Ag | Combinación de inhibidores de quinasa atr con sal de radio-223 |
WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
FI3651768T3 (fi) | 2017-07-13 | 2024-03-14 | Univ Texas | Heterosyklisiä ATR-kinaasin inhibiittoreita |
EP3661560A1 (en) | 2017-08-04 | 2020-06-10 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
CA3074719A1 (en) * | 2017-09-08 | 2019-03-14 | Bluevalley Pharmaceutical Llc | Substituted pyrrolopyridines as atr inhibitors |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2019110586A1 (en) | 2017-12-08 | 2019-06-13 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
RS65147B1 (sr) * | 2018-02-07 | 2024-02-29 | Wuxi Biocity Biopharmaceutics Co Ltd | Inhibitor atr i njegova primena |
JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | Atrキナーゼの複素環式阻害剤 |
CA3116230A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
EP3899004A2 (en) * | 2018-12-18 | 2021-10-27 | Astrazeneca AB | Pharmaceutical process and intermediates |
CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
GB201908536D0 (en) * | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
AU2020325416A1 (en) * | 2019-08-06 | 2022-02-03 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Crystalline form of ATR inhibitor and use thereof |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
JP2023502458A (ja) * | 2019-11-21 | 2023-01-24 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用 |
CN112939966B (zh) * | 2019-12-10 | 2023-03-24 | 武汉光谷亚太医药研究院有限公司 | 嘧啶衍生物、其制备及应用 |
TW202140474A (zh) * | 2020-01-17 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用 |
WO2021189036A1 (en) * | 2020-03-20 | 2021-09-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Taf1 inhibitors |
AU2021269764A1 (en) | 2020-05-11 | 2023-01-19 | Astrazeneca Ab | ATR inhibitors for the treatment of cancer |
US20230212165A1 (en) * | 2020-05-29 | 2023-07-06 | Shenzhen Lingfang Biotech Co., Ltd. | Fluoropyrrolopyridine compound and application thereof |
CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
IL299368A (en) | 2020-06-24 | 2023-02-01 | Astrazeneca Uk Ltd | A combination of an antibody-drug conjugate and an ATR inhibitor |
CA3185963A1 (en) * | 2020-07-13 | 2022-01-20 | Cheung Ling Cheng | Pyrazolopyrimidine compound used as atr kinase inhibitor |
US20230399302A1 (en) * | 2020-10-29 | 2023-12-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Process for the preparation of heteroaryl-substituted sulfur(vi) compounds |
TW202304457A (zh) | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
JP2024512558A (ja) | 2021-03-26 | 2024-03-19 | アストラゼネカ・アクチエボラーグ | 黒色腫のための組み合わせ治療 |
IT202100021863A1 (it) * | 2021-08-13 | 2023-02-13 | Univ Degli Studi Milano | Morfolino pirimidine per l’uso nella prevenzione e/o nel trattamento di stati di ipereccitabilità neuronale |
WO2023039573A1 (en) * | 2021-09-10 | 2023-03-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compounds for targeted degradation of taf1 |
CN116283960A (zh) * | 2021-12-21 | 2023-06-23 | 上海安诺达生物科技有限公司 | 取代的稠杂环化合物及其制备方法与应用 |
WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
DK0961780T3 (da) | 1997-02-12 | 2007-08-27 | Electrophoretics Ltd | Proteinmarkörer for lungecancer og anvendelse deraf |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
KR20080015482A (ko) | 1999-02-10 | 2008-02-19 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
EP1277738B1 (en) | 2000-04-27 | 2011-03-30 | Astellas Pharma Inc. | Condensed heteroaryl derivatives |
CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU2001266233B2 (en) | 2000-07-07 | 2006-06-29 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
KR100611853B1 (ko) | 2000-11-10 | 2006-08-11 | 에프. 호프만-라 로슈 아게 | 피리미딘 유도체 및 이의 신경펩타이드 y 수용체리간드로서의 용도 |
PL377821A1 (pl) | 2002-11-21 | 2006-02-20 | Chiron Corporation | 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu |
US20080058297A1 (en) | 2003-05-29 | 2008-03-06 | Synta Pharmaceuticals Corp. | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CA2586870A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
TW200720256A (en) | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
ES2473341T3 (es) | 2005-05-20 | 2014-07-04 | Methylgene Inc | Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF |
DE102005024494A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
ATE527253T1 (de) * | 2005-07-01 | 2011-10-15 | Irm Llc | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer |
WO2007013691A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
WO2007027855A2 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
KR101487027B1 (ko) | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
ZA200802685B (en) | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための4−(3−アミノピラゾール)ピリミジン誘導体 |
JPWO2007063868A1 (ja) | 2005-11-29 | 2009-05-07 | 東レ株式会社 | アリールメチレンウレア誘導体及びその用途 |
GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525083D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
BRPI0706395A2 (pt) | 2006-01-11 | 2011-03-22 | Astrazeneca Ab | composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
WO2007089768A2 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
WO2007105023A1 (en) | 2006-03-15 | 2007-09-20 | Csir | Modulation of phosphoryl transferase activity of glutamine synthetase |
JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
US8044068B2 (en) | 2006-04-04 | 2011-10-25 | Taisho Pharmaceutical Co., Ltd | Aminopyrrolidine compound |
MX2008013430A (es) | 2006-04-19 | 2009-01-26 | Novartis Vaccines & Diagnostic | Compuestos de indazol y metodos para la inhibición de cdc7. |
WO2007126043A1 (ja) | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
MX2009002046A (es) | 2006-08-24 | 2009-03-06 | Astrazeneca Ab | Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos. |
EP2057129A1 (en) | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
JP2010506902A (ja) * | 2006-10-16 | 2010-03-04 | ジーピーシー・バイオテック・インコーポレーテッド | ピリド[2,3−d]ピリミジン類およびキナーゼ阻害剤としてのそれらの使用 |
CA2683619A1 (en) | 2007-04-12 | 2008-10-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
CA2692725A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Compound - 946 |
EP2356112A1 (de) * | 2008-11-14 | 2011-08-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaromatische verbindungen zur verwendung als hif-inhibitoren |
UY32351A (es) * | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
-
2011
- 2011-06-08 SA SA111320519A patent/SA111320519B1/ar unknown
- 2011-06-09 BR BR112012031561A patent/BR112012031561B1/pt active IP Right Grant
- 2011-06-09 JP JP2013513758A patent/JP5721821B2/ja active Active
- 2011-06-09 WO PCT/GB2011/051074 patent/WO2011154737A1/en active Application Filing
- 2011-06-09 ES ES11725494.6T patent/ES2514325T3/es active Active
- 2011-06-09 MY MYPI2012701121A patent/MY158193A/en unknown
- 2011-06-09 RS RSP20140534 patent/RS53566B1/en unknown
- 2011-06-09 TW TW100120242A patent/TWI526208B/zh active
- 2011-06-09 PE PE2012002373A patent/PE20130306A1/es active IP Right Grant
- 2011-06-09 SG SG2012086112A patent/SG185711A1/en unknown
- 2011-06-09 KR KR1020137000590A patent/KR101820996B1/ko active IP Right Grant
- 2011-06-09 EP EP11725494.6A patent/EP2579877B1/en active Active
- 2011-06-09 PT PT117254946T patent/PT2579877E/pt unknown
- 2011-06-09 UY UY0001033440A patent/UY33440A/es not_active Application Discontinuation
- 2011-06-09 PL PL11725494T patent/PL2579877T3/pl unknown
- 2011-06-09 US US13/156,684 patent/US8252802B2/en active Active
- 2011-06-09 MX MX2012014477A patent/MX2012014477A/es active IP Right Grant
- 2011-06-09 CN CN201180039088.2A patent/CN103068391B/zh active Active
- 2011-06-09 CA CA2800203A patent/CA2800203C/en active Active
- 2011-06-09 NZ NZ604480A patent/NZ604480A/en unknown
- 2011-06-09 AU AU2011263491A patent/AU2011263491B2/en active Active
- 2011-06-09 SI SI201130280T patent/SI2579877T1/sl unknown
- 2011-06-09 DK DK11725494.6T patent/DK2579877T3/da active
- 2011-06-09 EA EA201201680A patent/EA022087B1/ru not_active IP Right Cessation
- 2011-06-10 AR ARP110102022A patent/AR081859A1/es active IP Right Grant
- 2011-09-06 UA UAA201215028A patent/UA109010C2/en unknown
- 2011-09-06 CU CU20120169A patent/CU24109B1/es active IP Right Grant
-
2012
- 2012-07-02 US US13/540,057 patent/US8552004B2/en active Active
- 2012-12-11 CR CR20120628A patent/CR20120628A/es unknown
- 2012-12-11 GT GT201200334A patent/GT201200334A/es unknown
- 2012-12-11 CO CO12224297A patent/CO6640270A2/es active IP Right Grant
- 2012-12-11 DO DO2012000310A patent/DOP2012000310A/es unknown
- 2012-12-11 EC ECSP12012334 patent/ECSP12012334A/es unknown
- 2012-12-11 NI NI201200184A patent/NI201200184A/es unknown
- 2012-12-11 CL CL2012003503A patent/CL2012003503A1/es unknown
-
2013
- 2013-01-10 ZA ZA2013/00255A patent/ZA201300255B/en unknown
- 2013-08-12 HK HK13109418.0A patent/HK1182019A1/xx unknown
- 2013-09-18 US US14/030,134 patent/US8999997B2/en active Active
-
2014
- 2014-10-03 HR HRP20140953AT patent/HRP20140953T1/hr unknown
- 2014-10-09 SM SM201400146T patent/SMT201400146B/xx unknown
-
2015
- 2015-02-26 US US14/631,961 patent/US9155742B2/en active Active
- 2015-09-21 US US14/859,567 patent/US9421213B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013528204A5 (ja) | ||
USRE49556E1 (en) | Compounds and compositions as protein kinase inhibitors | |
HRP20140953T1 (hr) | Morfolino pirimidini i njihova uporaba za lijeäśenje | |
ES2826950T3 (es) | Métodos para tratar cáncer y afecciones no neoplásicas | |
JP2014139226A5 (ja) | ||
JP2014523851A5 (ja) | ||
JP2015518894A5 (ja) | ||
AR087336A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina | |
JP2014526549A5 (ja) | ||
JP2017502940A5 (ja) | ||
JP2014505735A5 (ja) | ||
JP2016538313A5 (ja) | ||
JP2011500806A5 (ja) | ||
JP2016533366A5 (ja) | ||
RU2014151009A (ru) | Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы | |
JP2009515814A5 (ja) | ||
JP2017504635A5 (ja) | ||
JP2016528298A5 (ja) | ||
JP2014504646A5 (ja) | ||
JP2014526447A (ja) | キナーゼインヒビターとしてのベンゾニトリル誘導体 | |
RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
JP2016540803A5 (ja) | ||
JP2013523814A5 (ja) | ||
JP2019505594A5 (ja) | ||
JP2014510147A5 (ja) |